SCHEMBL24069060

SCHEMBL24069060

O=S(=O)(NCCCN1CCC(c2ccccc2)CC1)c1ccc2ccccc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 1/20 0.50
▸ DRD2 P14416 5/20 0.48
▸ DRD3 P35462 1/20 0.48
▸ HTR7 P34969 8/20 0.48
▸ HTR2A P28223 4/20 0.48
▸ HTR1A P08908 2/20 0.48
▸ SLC6A4 P31645 2/20 0.48
▸ SLC6A2 P23975 1/20 0.47
▸ HTR2C P28335 1/20 0.47
▸ HRH1 P35367 1/20 0.47
▸ PARP1 P09874 1/20 0.47
▸ PARP2 Q9UGN5 1/20 0.47
▸ SIGMAR1 Q99720 3/20 0.45
▸ CARM1 Q86X55 1/20 0.45
▸ PRMT6 Q96LA8 1/20 0.45
▸ HTR6 P50406 2/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24070176 0.94 CARM1 (0.50) BCHEDRD2DRD3HTR7HTR2A
SCHEMBL24069430 0.85 SLC6A2 (0.57) HTR7SLC6A4SLC6A2SIGMAR1CARM1
SCHEMBL29022565 0.83 HTR7 (0.66) DRD2DRD3HTR7HTR2AHTR1A
SCHEMBL24069064 0.83 HTR7 (0.66) BCHEDRD2DRD3HTR7HTR2A
SCHEMBL25758563 0.81 HTR7 (0.69) DRD2HTR7HTR2AHTR1AHTR2C
SCHEMBL25759707 0.79 BCHE (0.63) BCHEDRD2HTR7HTR2AHTR1A
SCHEMBL24070172 0.79 SLC6A2 (0.62) SLC6A4SLC6A2CARM1PRMT6
SCHEMBL29022592 0.77 HTR7 (0.67) HTR7HTR2AHTR1ASLC6A4HTR2C
SCHEMBL24069065 0.77 HTR7 (0.56) BCHEHTR7HTR1ASIGMAR1CARM1
SCHEMBL24069067 0.76 HTR7 (0.56) BCHEHTR7SLC6A4SLC6A2SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116157124-A Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient 大邱庆北尖端医疗产业振兴财团 2023-05-23 — — CN claimed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 — — US disclosed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 — — US disclosed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 — — US disclosed
CN-116157124-A Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient 大邱庆北尖端医疗产业振兴财团 2023-05-23 — — CN disclosed
EP-4159718-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2023-04-05 — — EP disclosed
WO-2021241875-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS 재단법인 대구경북첨단의료산업진흥재단 2021-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS SLC6A2, SLC6A3, SLC6A4 BCHE 1086/4885DRD2 4/4885DRD3 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback